Across BlueRock, we strive to hire the best talent. To do that, we take an open-minded approach to career trajectory and experience. Look a little closer and you will see a diverse workforce with employees who have transitioned from academia to industry, across industries, […]
I really love working in IT – I have an inherent need to solve problems and be a bit of a detective. Out of school I didn’t want to do IT. I loved computers but I thought doing it as a job would put […]
My name is Carlos Antonio Paladini. One of my early memories growing up in Lima, Peru and Sao Paulo, Brazil was reading about Che Guevara. Despite personally disagreeing with aspects of his philosophy, I remember being struck by a declassified CIA report describing Che […]
CAMBRIDGE, Mass., July 26, 2021 — BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth […]
Strengthens leadership team and adds deep expertise in engineered cell therapies CAMBRIDGE, Mass., March 03, 2020 (GLOBE NEWSWIRE) — BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team. In his role as Chief Scientific Officer, Dr. […]
Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs CAMBRIDGE, Mass., March 18, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment […]
CAMBRIDGE, Mass., Nov. 26, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment of Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer. In her new role, […]
CAMBRIDGE, Mass., Oct. 3, 2018 /PRNewswire/ — BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, announced today that Dr. Emile Nuwaysir, the Company’s President and Chief Executive Officer, has been elected […]
Appointment strengthens the leadership team and accelerates the company’s establishment of its novel Cell+Gene platform CAMBRIDGE, Mass., Sept. 20, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced […]
CAMBRIDGE, Mass., Dec. 1, 2017 — BlueRock Therapeutics today announced the appointment of Derek Hei, Ph.D., as senior vice president, manufacturing, quality and regulatory. “We are thrilled to have Derek join our team. He is a strategic leader with extensive experience in cell and gene […]
